Form 4: Citius Oncology CFO Granted Stock Options, Forms Power of Attorney

Jaime Bartushak, CFO of Citius Oncology, received stock options and granted power of attorney for SEC filings.

Summary

• Jaime Bartushak, the Chief Financial Officer of Citius Oncology, Inc., was granted stock options to purchase 466,667 shares of common stock on August 12, 2024.
• The exercise price of these options is $2.15 per share.
• The options vest over three years, beginning July 5, 2023, with a portion vesting monthly for the first year and the remainder vesting on the second and third anniversaries.
• Bartushak also granted power of attorney to Alexander M. Donaldson and Lorna A. Knick to execute SEC filings on her behalf, including Forms ID, 3, 4, 5, and Schedules 13D/13G.
• This power of attorney is effective until Bartushak is no longer required to file these forms or until revoked in writing.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and legal formalities, suggesting a neutral to slightly positive sentiment due to incentivizing key personnel.

Positives

• The granting of stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, comparable to companies like Amgen, Gilead Sciences, and Biogen.
• The vesting schedule of three years is also typical, aligning with industry norms for long-term incentive plans.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates